1 / 14

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach?

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? Peri -operative chemotherapy . Josep Tabernero, MD PhD Medical Oncology Department Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology Barcelona.

zytka
Télécharger la présentation

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? Peri-operative chemotherapy  Josep Tabernero, MD PhD Medical Oncology Department Valld’Hebron University Hospital & Valld’Hebron Institute of Oncology Barcelona Great Debates & Updates in GI Malignancies NY, March 29th, 2014

  2. GASTRIC meta-analysis on individual data: Survival OS, CT + surgery OS, surgery alone DFS, CT + surgery DFS, surgery alone Survival proportion 77% of the recurrences occurred during the first 3 years OS HR = 0.81 95% CI = 0.74-0.87 p = 0.03 Follow-up (years) Gastric cancer meta-analysis. JAMA 2010;303:1729-37

  3. But adjuvant chemotherapy (radiotherapy) cannot be administered to all patients… 50 - 70% may receive adjuvant treatment but tolerance is poor: - Treatment delays - Dose reductions - Early termination Surgery “in the Real life” BUT: - Delayed surgical recovery - Poor food intake - Dumping syndrome - Poor performance status - Treatment refusal ~30 - 50%? Interest of pre/peri-operative treatment in resectable but infiltrating tumor

  4. Rationale for peri-operative or pre-operative chemotherapy • To offer chemotherapy treatment to a larger number of patients • To downsize/downstage the tumor • To facilitate the surgery • To decrease the risk of local recurrence and distant metastasis • To increase the overall survival • To offer a better safety profile and treatment tolerability • To offer a more effective treatment (compliance)

  5. Perioperative or pre-operative chemotherapy Preoperative chemotherapy Postoperative chemotherapy Surgery R Surgery Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

  6. Stage – Inclusion criteria Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

  7. Pathology Results Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

  8. Overall Survival Cunningham D et al. N Engl J Med 2006;355:11-20; Ychou Met al. J Clin Oncol 2011;29:1715-1721; Schuhmacher C et al. J Clin Oncol 2010;28:5210-5218.

  9. MAGIC - Survival Cunningham D et al. N Engl J Med 2006;355:11-20

  10. Meta-analysis of pre/peri-operative treatment Survival Ge L et al. World J Gastroenterol 2012;18:7384-7393

  11. Comparison between adjuvant and pre/perioperative treatment Modified from Philippe Rougier

  12. Pre/perioperative treatment – Take home messages • Feasible and safe • Compliance: 90% preoperative, 50-70% post-operative • Significantly downstage/downsize the tumor and increase R0 resections • Does not increase perioperative morbidity and mortality • Significantly improves OS (13% at 5-yr in the largest studies)

  13. MAGIC – B – STO-03 Randomised ECX Repeated every 21 days for 3cycles ECX + Bevacizumab Repeated every 21 days for 3cycles Surgery 5 wk break from last pre-op chemo (8 wk break from last bevacizumab) 6-10 wk break before post-op chemo ECX Repeated every 21 days for 3cycles ECX + Bevacizumab Repeated every 21 days for 3cycles Maintenance Bevacizumab Every 21 days for 6 doses

  14. ³ “MAGIC”(3xECC) 15 Lymph nodes 45 Gy/25 fx + no splenectomy capecitabine dd Epirubicine / Cisplatin /Capecitabine cisplatin 1 - 5x pw 3D - CRT/IMRT CRITICS Preoperative chemotherapy 3x ECC q 3wks D1 + surgery 3x ECC q 3wks QoL R Preoperative chemotherapy 3x ECC q 3wks D1 + surgery Chemoradiation Tissue banking • Stratified for: • Centre • Histological type • Localisation of tumour

More Related